Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes

Modern Pathology

Volumn 28, Issue 2, 2015, Pages 248-260

  Agaimy, Abbas ^a   Haller, Florian ^a   Frohnauer, Judith ^a   Schaefer, Inga Marie ^b,c   Ströbel, Philipp ^c   Hartmann, Arndt ^a   Stoehr, Robert ^a   Klöppel, Günter ^d  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYTOKERATIN; K RAS PROTEIN; PROTEIN DERIVATIVE; PROTEIN SMARCB1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; DNA BINDING PROTEIN; KRAS PROTEIN, HUMAN; NONHISTONE PROTEIN; ONCOPROTEIN; RAS PROTEIN; SMARCB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL SUBPOPULATION; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GIANT CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; UNDIFFERENTIATED CARCINOMA; BIOSYNTHESIS; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; PATHOLOGY; RHABDOID TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RHABDOID TUMOR; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922010432     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.100     Document Type: Article

References (39)

1. Wick MR, Ritter JH, Dehner LP. Malignant rhabdoid tumors: a clinicopathologic review and conceptual discussion. Semin Diagn Pathol 1995;12:233-248.
2. Fanburg-Smith JC, Hengge M, Hengge UR, et al. Extrarenal rhabdoid tumors of soft tissue: a clinicopathologic and immunohistochemical study of 18 cases. Ann Diagn Pathol 1998;2:351-362.
3. Kerl K, Holsten T, Frühwald MC. Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy. Pediatr Hematol Oncol 2013;30:587-604.
4. Sommers SC, MeissnerWA. Unusual carcinomas of the pancreas. Arch Path 1954;58:101-111.
5. Guillan RA. Pleomorphic adenocarcinoma of the pancreas. An analysis of five cases. Cancer 1968;21: 1072-1079.
6. Alguacil-Garcia A, Weiland LH. The histologic spectrum, prognosis, and histogenesis of the sarcomatoid carcinoma of the pancreas. Cancer 1977;39:1181-1189.
7. Tschang TP, Garza-Garza R, Kissane JM. Pleomorphic carcinoma of the pancreas: an analysis of 15 cases. Cancer 1977;39:2114-2126.
8. Reyes CV, Crain S, Wang T. Pleomorphic giant cell carcinoma of the pancreas: a review of nine cases. J Surg Oncol 1980;15:345-348.
9. Hoorens A, Prenzel K, Lemoine NR, et al. Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin. J Pathol 1998;185:53-60.
10. Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). World Health Organization Classification of Tumours of the Digestive System. IARC Press: Lyon, 2010.
11. Solcia E, Capella C, Klöppel G. AFIP Atlas of Tumor Pathology: Tumors of the Pancreas, 3rd edn. Series, Fascicle 20. The American Registry of Pathology: Washington, DC, 1997.
12. Hruban RH, Pitman MB, Klimstra DS. AFIP Atlas of Tumor Pathology: Tumors of the Pancreas, 4th Series. Fascicle 6. The American Registry of Pathology: Washington, DC, 2007.
13. Nishihara K, Katsumoto F, Kurokawa Y, et al. Anaplastic carcinoma showing rhabdoid features combined with mucinous cystadenocarcinoma of the pancreas. Arch Pathol Lab Med 1997;121:1104-1107.
14. Al-Nafussi A, O'Donnell M. Poorly differentiated adenocarcinoma with extensive rhabdoid differentiation: clinicopathological features of two cases arising in the gastrointestinal tract. Pathol Int 1999;49:160-163.
15. Kuroda N, Sawada T, Miyazaki E, et al. Anaplastic carcinoma of the pancreas with rhabdoid features. Pathol Int 2000;50:57-62.
16. Chadha MK, LeVea C, Javle M, et al. Anaplastic pancreatic carcinoma. A case report and review of literature. J Pancreas 2004;5:512-515.
17. Cho YM, Choi J, Lee OJ, et al. SMARCB1/INI1 missense mutation in mucinous carcinoma with rhabdoid features. Pathol Int 2006;56:702-706.
18. Jamali M, Serra S, Chetty R. Adenosquamous carcinoma of the pancreas with clear cell and rhabdoid components. A case report. J Pancreas 2007;8:330-334.
19. Kuroda N, Iwamura S, Fujishima N, et al. Anaplastic carcinoma of the pancreas with rhabdoid features and hyaline globule-like structures. Med Mol Morphol 2007;40:168-171.
20. Judkins AR. Immunohistochemistry of INI1 expression: a new tool for old challenges in CNS and soft tissue pathology. Adv Anat Pathol 2007;14:335-339.
21. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74-79.
22. Biegel JA, Tan L, Zhang F, et al. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res 2002;8:3461-3467.
23. Bittesini L, Dei Tos AP, Fletcher CD. Metastatic malignant melanoma showing a rhabdoid phenotype: further evidence of a non-specific histological pattern. Histopathology 1992;20:167-170.
24. Perry A, Fuller CE, Judkins AR, et al. INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. Mod Pathol 2005;18:951-958.
25. Donner LR, Wainwright LM, Zhang F, et al. Mutation of the INI1 gene in composite rhabdoid tumor of the endometrium. Hum Pathol 2007;38:935-939.
26. Agaimy A, Rau TT, Hartmann A, et al. SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. Am J Surg Pathol 2014;38:910-920.
27. Agaimy A, Koch M, Lell M, et al. SMARCB1/INI1-Deficient Sinonasal Basaloid Carcinoma: A Novel Member of the Expanding Family of SMARCB1 Deficient Neoplasms. Am J Surg Pathol; advance online publication, 14 May 2014 (e-pub ahead of print).
28. Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol 2011;35:e47-e63.
29. Krasinskas AM, Moser AJ, Saka B, et al. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas. Mod Pathol 2013;26:1346-1354.
30. Lurkin I, Stoehr R, Hurst CD, et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One 2010;5:e8802.
31. Nardon E, Glavac D, Benhattar J, et al. A multicenter study to validate the reproducibility of MSI testing with a panel of 5 quasimonomorphic mononucleotide repeats. Diagn Mol Pathol 2010;19:236-242.
32. Layfield LJ, Bentz J. Giant-cell containing neoplasms of the pancreas: an aspiration cytology study. Diagn Cytopathol 2008;36:238-244.
33. Nakajima A, Takahashi H, Inamori M, et al. Anaplastic carcinoma of the pancreas producing granulocytecolony stimulating factor: a case report. J Med Case Rep 2008;2:391.
34. Lee HJ, Lee OJ, Jang KT, et al. Combined loss of E-cadherin and aberrant b-catenin protein expression correlates with a poor prognosis for small intestinal adenocarcinomas. Am J Clin Pathol 2013;139:167-176.
35. Streit M, Schmidt R, Hilgenfeld RU, et al. Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. Recent Results Cancer Res 1996;142:19-50.
36. Pancione M, Remo A, Sabatino L, et al. Rightsided rhabdoid colorectal tumors might be related to the serrated pathway. Diagn Pathol 2013; 8:31.
37. Guillou L, Wadden C, Coindre JM, et al. 'Proximaltype' epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol 1997;21:130-146.
38. Sullivan LM, Folpe AL, Pawel BR, et al. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions. Mod Pathol 2013;26:385-392.
39. Goggins M, Offerhaus GJ, Hilgers W, et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 1998;152:1501-1507.